Advance Auto Parts, Inc. vs ARK Genomic Revolution ETF — how do they compare? Advance Auto Parts, Inc. trades at $53.07 (market cap $3.19B), while ARK Genomic Revolution ETF trades at $44.43. The key difference: Advance Auto Parts, Inc. pays a 1.89% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Advance Auto Parts, Inc. nearer its low. Which is the better fit depends on your goals.
| AAP | ARKG | |
|---|---|---|
Market Cap | $3.19B | — |
Sector | Consumer Cyclical | Sector/Thematic |
52-Week High | $64.17 | $44.55 |
52-Week Low | $38.75 | $24.02 |
Enterprise Value | $5.47B | — |
Dividend Yield | 1.89% | — |
Signals from Pluang's Aura AI — not financial advice
Advance Auto Parts (AAP) trades at $53.59, down 3.84% on the day, with a bearish technical signal. Recent earnings have consistently beaten estimates, but profitability remains thin with a net margin of 0.51%. The company is executing a turnaround focused on professional sales and supply chain restructuring. Cash flow trends show heavy financing activity supporting operations.
The outlook is mixed; analyst consensus is a Buy with a $61.30 price target, but high debt and weak operating cash flow pose risks. Upside depends on successful execution of the restructuring plan to improve margins and stabilize revenue. Near-term support is at $52, with resistance at $55.
No Aura AI signal available yet.
Trailing returns across standard periods
Advance Auto Parts is one of the industry's largest retailers of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in North America. Advance operated 4,972 stores as of the end of 2021, in addition to servicing 1,317 independently owned Carquest stores. The company's Worldpac unit is a premier distributor of imported original-equipment parts. Advance derived 58% of its 2021 sales from commercial clients, up from 30%-40% before the General Parts deal.
Read more on AAP →ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →